27 October 2018

PRESS RELEASE – IL-17 patent granted in Europe
27 October 2018

Press Release Lyon, October 8, 2018 Interleukin-17 patent granted in Europe Lyon, France, October 8, 2018 – OREGA Biotech, the biotech company committed to the development of novel monoclonal antibody-based immunotherapy for cancer patients, announced the grant of patent EP2569335 by the European Patent Office. This patent covers IL-17A neutralizing antibodies for use as a therapeutic tool to increase the response to other chemotherapeutic agents. “The delivery of this European Patent is another important milestone for OREGA Biotech; it is the fifth issued patent related to our IL‑17 programs”, commented Jeremy Bastid, Chief Operating Officer of OREGA Biotech. “Intellectual property is a key asset in OREGA’s target discovery programs. Our capacity to obtain broad claims covering novel cancer targets offers a valuable competitive advantage.” Read the press release.
[ Read more ]
23 October 2018

AstraZeneca and Innate Pharma enter into partnership for the development of CD39 mAbs
23 October 2018

On October 23, 2018, Innate Pharma announced that it had entered into a development collaboration and option for further co-development and co-commercialisation with AstraZeneca for its CD39 monoclonal antibody, IPH5201.
[ Read more ]
17 June 2018

Meet us at the 2018 Bio Convention to be held in Boston
17 June 2018

Jeremy Bastid, Chief Operating Officer, will attend the 2018 BIO International Convention, to be held in Boston, Massachusetts, June 4-7, 2018.
[ Read more ]
27 April 2017

IL-17B program to be presented at AACR 2017
27 April 2017

OREGA will present latest in vivo data of its IL-17B program at the upcoming AACR annual conference to be held in Washington DC. SESSION PO.IM02.06 – Cytokines: The First Modern Immunotherapies April 3, 2017, 8:00 AM – 12:00 PM 1602 / 10 – Generation of anti-IL-17B antibodies neutralizing IL-17B-mediated alterations of the immune microenvironment, promotion of tumor cell initiating capacity and chemoresistance
[ Read more ]